EFFICACY OUTCOMES BY SYMPTOM-BASED RESPONSE STATUS AFTER INDUCTION: WEEK-48 RESULTS FROM THE GALAXI 1 TRIAL OF GUSELKUMAB IN CROHN’S DISEASE

Julian Panés  1     Anita Afzali  2     David T. Rubin  3     Bruce E. Sands  4     Walter Reinisch  5     Geert R. D'Haens  6     Mario Gomez  7     Natalie Terry  8     Aparna Sahoo  8     Mary Ellen Frustaci  9     Zijiang Yang  9     William Sandborn  10     Remo Panaccione  11     Tadakazu Hisumatsu  12     Silvio Danese  13     Jane Andrews  14     Brian G. Feagan  15    
1 Hospital Clínic Barcelona, Barcelona, Spain
2 Ohio State University, Hilliard, United States
3 University of Chicago Medicine, Chicago, United States
4 Icahn School of Medicine at Mount Sinai, New York, United States
5 Medical University of Vienna, Vienna, Austria
6 AMC Amsterdam Inflammatory Bowel Disease Centre - Academic Medical Center, AMC Amsterdam Inflammator, Amsterdam, Netherlands
7 Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham
8 Janssen Research & Development, LLC, Spring House
9 Janssen Research and Development, LLC, Spring House, United States
10 University of California San Diego, La Jolla, United States
11 University of Calgary, Calgary, Canada
12 Kyorin University School of Medicine, Kyorin, Japan
13 Vita-Salute San Raffaele University - IRCCS San Raffaele Scientific Institute, Milan, Italy
14 Royal Adelaide Hospital, Adelaide, Australia
15 The University of Western Ontario, London, Canada

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing